LONDON, 14 February 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, notes that its portfolio company, Disc Medicine, today announced a $62.5 million financing to advance its portfolio of novel haematology programmes.

The financing was led by Bain Capital Life Sciences, who contributed $50 million, with participation from existing investors, Access Biotechnology and OrbiMed.

The announcement can be accessed on Disc Medicine’s website at: https://ir.discmedicine.com